There will be plenty of debate about ORAL Surveillance, as there should be. We will see more granular data, as we should. Whatever the case, it's hard to argue that there's no cancer risk with tofacitinib vs TNFi in RA, at least for some patients at higher risk. #ACR21 @RheumNow